Sensorion is considering an initial public offering in the United States

Sensorion, a biotechnology company specializing in hearing therapies, announced the confidential filing of a proposed registration with the SEC. This move aims for a potential initial public offering (IPO) in the United States, including the possibility of listing its American Depositary Shares (ADS) on a U.S. market. This step remains contingent on market developments and other factors.

Although this filing does not constitute an offer to sell or a solicitation of securities, it marks a strategic step forward for Sensorion in its international expansion. In compliance with the Securities Act of 1933, Sensorion continues its mission to address an unmet medical need in the field of hearing loss.